Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GeneDx Holdings (WGS) EBT (2020 - 2025)

Historic EBT for GeneDx Holdings (WGS) over the last 6 years, with Q3 2025 value amounting to -$7.4 million.

  • GeneDx Holdings' EBT rose 1161.62% to -$7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year increase of 10297.65%. This contributed to the annual value of -$52.6 million for FY2024, which is 7021.44% up from last year.
  • GeneDx Holdings' EBT amounted to -$7.4 million in Q3 2025, which was up 1161.62% from $10.6 million recorded in Q2 2025.
  • GeneDx Holdings' 5-year EBT high stood at $32.7 million for Q3 2021, and its period low was -$308.7 million during Q4 2022.
  • Over the past 5 years, GeneDx Holdings' median EBT value was -$40.2 million (recorded in 2021), while the average stood at -$56.6 million.
  • In the last 5 years, GeneDx Holdings' EBT soared by 15781.33% in 2021 and then crashed by 66812.49% in 2022.
  • GeneDx Holdings' EBT (Quarter) stood at -$40.2 million in 2021, then plummeted by 668.12% to -$308.7 million in 2022, then soared by 91.52% to -$26.2 million in 2023, then skyrocketed by 120.68% to $5.4 million in 2024, then plummeted by 236.46% to -$7.4 million in 2025.
  • Its EBT was -$7.4 million in Q3 2025, compared to $10.6 million in Q2 2025 and -$6.1 million in Q1 2025.